arrow
S

Shahneen Sandhu

University of Melbourne
H指数:81
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

在GNAQ/GNA11突变型黑色素瘤中具有Gq/11抑制剂载荷的抗PMEL抗体−药物偶联物:一项1期临床试验

2026-07-130
OA
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer

复发性肿瘤内异质性是转移性前列腺癌的标志

2026-06-190
OAAI
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma

肿瘤内T细胞和树突状细胞在黑色素瘤免疫治疗反应中形成原位原型

2026-06-010
PRE
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer

复杂结构变异的趋同进化驱动转移性前列腺癌的疗法抗性

2026-04-150
OAAI
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

早期PSMA上调对恩扎卢胺±177Lu-PSMA-617治疗高危转移性去势抵抗性前列腺癌疗效的预测价值:随机II期ENZA-p试验的亚组研究

2026-04-010
PRE
Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma

微生物组衍生的丁酸盐促进FOXO1诱导的干细胞特性程序,并维持CD8+ T细胞对黑色素瘤的免疫力

Immunity
IF26.3
2025-11-030
PRE
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

在临床上可检测的III期黑色素瘤中,新辅助免疫治疗后,通过减少肿瘤床检查,病理反应计算评估仍然准确。

2025-11-010
PRE
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Niraparib和abiraterone acetate联合prednisone治疗HRR缺陷型转移性去势敏感前列腺癌:一项随机III期试验

2025-10-070
OAAI
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

SPARC:标准化前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分析与报告共识:一项德尔菲分析

2025-09-130
PREAI
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值:一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究

2025-07-300
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer

个体内表观遗传异质性是晚期前列腺癌表型亚型的基础

2025-07-010
OAAI
Immune checkpoint inhibitor-associated myocarditis: a novel risk score

免疫检查点抑制剂相关心肌炎:一种新型风险评分

2025-06-180
PRE
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial

Niraparib和Abiraterone Acetate联合Prednisone治疗转移性去势抵抗性前列腺癌:MAGNITUDE III期试验最终总生存分析

2025-05-050
OAAI
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Fdg-pet与黑色素瘤新辅助免疫治疗的病理反应和生存率的关系

2025-03-250
OA